Analystreport

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $19.00 price target on the sto

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com